Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 3Unknown 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 102Breast Neoplasms 10Neoplasm Metastasis 8Prostatic Neoplasms, Castration-Resistant 6Triple Negative Breast Neoplasms 5Castration-resistant Prostate Cancer 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3Prostate Cancer Metastatic 2Prostate Adenocarcinoma 2Ovarian Neoplasms 2Neoplasms 2Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2Metastatic Castration-Resistant Prostate Cancer 2Metastatic Castration Resistant Prostate Cancer 2Castration Resistant Metastatic Prostate Cancer 2Carcinoma, Hepatocellular 2Adenocarcinoma of the Prostate 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Ureteral Diseases 1Thrombocytosis 1Stomach Neoplasms 1Solid Tumor 1Salivary Cancer 1Recurrent Endometrial Endometrioid Adenocarcinoma 1

Interventions

enzalutamide 4abiraterone 2Radiotherapy 2Metastasectomy 2Abiraterone Acetate 2testosterone enanthate 1pembrolizumab 1Radium-223 1Radiosurgery 1Prednisone 1Ketoconazole 1Injections 1Hydrocortisone 1Flutamide 1Crizotinib 1Control Groups 1Carboplatin 1Calcitriol 1Blood Specimen Collection 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Castration-resistant Prostate Cancer × enzalutamide × Clear all
NCT02207504 2022-01-06

Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 1 Completed
24 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT02346578 2021-09-16

Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.

Osaka City University

Phase 2 Completed
104 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT03305224 2021-09-09

CORE-OCU

Osaka City University

Phase 2 Unknown
10 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT02429193 2020-01-13

BARRIER-P

University Health Network, Toronto

Phase 2 Completed
16 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡